|Ms. Lori A. Holmes-Woods||CEO & Director||392.94k||N/A||1962|
|Mr. William A. Cavanagh III||Chief R&D Officer||258.8k||N/A||1966|
|Mr. Jonathan R. Hunt||CFO & Co-Principal Financial Officer||N/A||N/A||1967|
|Ms. Jennifer Streeter||COO & VP of HR||N/A||N/A||1970|
|Mr. Mark J. Austin CPA||Controller, Co-Principal Financial & Principal Accounting Officer and Corp. Sec.||N/A||N/A||1987|
|Ms. Krista Cline||Sr. Director of Operations & Corp. Sec.||N/A||N/A||1982|
Isoray, Inc., through its subsidiary, IsoRay Medical, Inc., develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States and internationally. The company produces CS-1 Cesium-131 brachytherapy seeds for the treatment of prostate, brain, lung, head and neck, gynecological, pelvic/abdominal, and colorectal cancers, as well as ocular melanoma. It sells its products to facilities or physician practices that utilize multiple surgical facilities at which primarily prostate brachytherapy procedures are performed. Isoray, Inc. was founded in 1998 and is headquartered in Richland, Washington.
Isoray, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.